Cardiometabolic risk is linked to a cluster of modifiable factors, including established risk factors such as obesity, dyslipidaemia, raised blood pressure, and 'nontraditional' risk factors closely related to central (especially intra-abdominal) adiposity. These 'nontraditional' risk factors include dysfunction of inflammation, coagulation, platelets, fibrinolysis, lipoproteins, endothelium, plaque instability, and miscellaneous biological processes. Both the established ('traditional') and emerging ('nontraditional') cardiometabolic risk factors are components of the metabolic syndrome.
In patients with known or suspected cardiometabolic diseases, biomarkers are increasingly being explored as indicators of disease presence, severity or activity, prognosis and therapeutic efficacy. Many biomarkers have been proposed for prediction of the macrovascular (and microvascular) complications of cardiometabolic diseases. This review provides background information on biomarkers, and an assessment of the possible utility of biomarkers in clinical trials and drug development programmes that include measurement of cardiometabolic risk.
Vasan RSBiomarkers of cardiovascular disease: molecular basis and practical considerations . Circulation2006;113:1335-62.
2.
Biomarkers Definitions Working Group.Biomarkers and surrogate end points: Preferred definitions and conceptual framework. Clin Pharmacol Ther2001;69:89-95.
3.
Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Europ Heart J2007;28:88-136.
4.
Fonseca V.Risk factors for coronary heart disease in diabetes. Ann Intern Med2000;133:154-6.
5.
Eckel R., Grundy S., Zimmet P.Metabolic syndrome. Lancet2005; 365:1415-28.
6.
Koenig W., Khuseyinova N.Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arterioscler Thromb Vasc Biol2007;27:15-26.
7.
Ridker PM, Brown NJ, Vaughan DE et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation2004;109:(suppl 4) 6-19.
8.
Musunuru K., Abraham J., Blumenthal RSCriteria for clinical use of biomarkers. Endocrine2006;4:6-9.
9.
Mora S., Rrfai N., Ridker PMAdditive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation2006;114:381-7.
10.
Hansson GKInflammation, Atherosclerosis, and Coronary Artery Disease. N Eng J Med2005 ;352:1685-95.
11.
L Ridker PMClinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation2003;107:363-9.
12.
Lloyd-Jones DM, Liu K., Tian L. et al. Narrative Review: Assessment of CReactive Protein in Risk Prediction for Cardiovascular Disease . Ann Intern Med2006;145:35-42.
13.
Kohler HP, Grant PJPlasminogen-activator inhibitor type 1 and coronary artery disease . N Eng J Med2000;342:1792-801.
14.
Kershaw EE, Flier JSAdipose tissue as an endocrine organ. J Clin Endo Metab2004;89:2548-56.
15.
Schulze MB, Rimm EB, Shah I. et al. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care2004;27:1680-7.
16.
Yu JG, Javorschi S., Havener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes2002;51:2968-74.
17.
Goldstein BJ , Scalia R.Adiponectin: a novel adipokine linking adipocyte and vascular function. J Clin Endo Metab2004 ;89:2563-8.
18.
Cowie MRB-type natriuretic peptide testing: where are we now?Heart2004;90:725-6.
19.
Konstam MANatriuretic Peptides and Cardiovascular Events - More Than a Stretch . JAMA2007;297:212-14.
20.
Tarnow L., Gall MA, Hansen BC et al. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia2006;49:2256-62.
21.
Bell DSH.Heart failure in diabetes. Diabetes Care2003 ;26:2433-41.
22.
Nesto RW, Bell D., Bonoe RO et al. Thiazolidinediones use, fluid retention, and congestive heart failure. Diabetes Care2004;27:256-63.
23.
Wang TJ, Gona P., Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Eng J Med2006;355:2631-9.
24.
Ridker PM, Buring JE, Rifai N., Cook NRDevelopment and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA2007;297:611-19.
25.
Psaty BM, Furberg CDRosiglitazone and cardiovascular risk. N Eng J Med2007,10.1056/NEJME078099 (accessed at www.nejm.org, May 21st, 2007).
